ClinicalTrials.gg
CompletedNCT00360698Basal PlusUpdated Aug 8, 2011Results posted

Insulin Glulisine in Type 2 Diabetic Patients

A Phase 4 interventional study of Insulin Glargine and Glimepiride in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 3 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-08-08.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. insulin glulisine · Diabetes Mellitus, Type 2.

Enrollment
18th of 25
106 · median 281
Started
2006
with 1 other
Phase 4
14 of 26
none open now
Registered
10th of 26
by date
Lead sponsor
19 of 26
Sanofi

Among the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2, this one is the 18th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2006, is one of 14 in phase 4, and was the 10th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About insulin glulisine

insulin glulisine: first FDA approval 2004 (APIDRA SOLOSTAR), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 as a file.
02

Study summary

To evaluate the efficacy of a single injection of glulisine before the main meal added to insulin glargine plus oral antidiabetic drugs (OADs) compared to insulin glargine plus OADs in Type 2 diabetic patients poorly controlled with basal insulin plus OADs.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diabetes Mellitus, Type 2
  • 25 \< \< 45 kg/m²
  • 7,5% \< \< 9%
  • Treated with a basal insulin (NPH, Insulin Zinc, Insulin glargine or Insulin detemir), and at least 1g metformin daily, for more than 3 months

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Treatment with OADs only
  • Treatment with thiazolidinediones, with exenatide or with pramlintide
  • Treatment with an insulin other than basal insulin (Premix, rapid insulin, fast-acting insulin analogue)
  • Active proliferative diabetic retinopathy,
  • Pregnancy (women of must have a negative pregnancy test at study entry and effective )
  • Breast-feeding
  • History of to the study drugs or to drugs with a similar chemical structure.
  • Treatment with systemic in the 3 months prior to study entry
  • Treatment with any product in the 2 months prior to study entry
  • Previous treatment with insulin glulisine
  • Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol
  • cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult
  • Impaired hepatic function
  • Impaired renal function
  • History of drug or alcohol abuse

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Other
    insulin glulisine+insulin glargine+metformin+glimepiride

    Bolus arm

    Drug: Insulin Glargine · Drug: Glimepiride · Drug: Insulin Glulisine · Drug: Metformin

  • Other
    insulin glargine+metformin+glimepiride

    Control arm

    Drug: Insulin Glargine · Drug: Glimepiride · Drug: Metformin

Interventions

06

What researchers measure

Primary outcomes

  1. Patients With Glycosylated Haemoglobin (HbA1c) Value < 7%

    Glycosylated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow -up in diabetic patients. this parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c \<7%

    Time frame: at the end of treatment (week 24)

Secondary outcomes

  1. Glycosylated Haemoglobin (HbA1c) Value

    Time frame: at the end of treatment (week 24)

  2. Change in Glycosylated Haemoglobin (HbA1c) Value

    Time frame: from baseline to the end of treatment (week 24)

  3. Daily Mean Plasma Glucose

    Time frame: at the end of treatment (week 24)

  4. Change in Daily Mean Plasma Glucose

    Time frame: from baseline to the end of treatment (week 24)

  5. Change in Weight

    Time frame: from baseline to the end of treatment (week 24)

  6. Daily Dose of Insulin Glargine

    Mean of 3 daily doses reported during the week prior to the final visit

    Time frame: at the end of treatment (week 24)

  7. Daily Dose of Insulin Glulisine

    Mean of 3 daily doses reported during the week prior to the final visit

    Time frame: at the end of treatment (week 24)

  8. Rate of Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL

    Time frame: during treatment period (12 weeks)

  9. Rate of Nocturnal Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL

    Time frame: during treatment period (12 weeks)

  10. Rate of Severe Symptomatic Hypoglycemia

    Time frame: during treatment period (12 weeks)

07

Results

Posted Dec 2, 2009

Participant flow

Run-In
Participant flow — Run-In
MilestoneInsulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+Glimepiride
Started0135
Completed0125
Not completed010
Withdrew: Physician decision01
Withdrew: Withdrawal by subject02
Withdrew: Non compliance with treatment procedure01
Withdrew: Sponsor request02
Withdrew: Patient did not meet inclusion criteria01
Withdrew: Patient personal reasons02
Withdrew: Need of insulin with meals01
Treatment Period
Participant flow — Treatment Period
MilestoneInsulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+Glimepiride
Started4957
Completed4856
Not completed11
Withdrew: Non compliance with treatment procedure10
Withdrew: Early termination by error01

Outcome measures

PrimaryPatients With Glycosylated Haemoglobin (HbA1c) Value < 7%

Glycosylated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow -up in diabetic patients. this parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c \<7%

Time frame:
at the end of treatment (week 24)
Reported as:
Number · percentage of participants
Patients With Glycosylated Haemoglobin (HbA1c) Value < 7%
percentage of participantsInsulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+Glimepiride
Patients With Glycosylated Haemoglobin (HbA1c) Value < 7%22.48.8
Statistical analysis
  • Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride vs Insulin Glargine+Metformin+Glimepiride · Chi-squared · p = 0.0499 · Risk difference (rd): 13.68 · 95% CI 0.01 to 28.37Difference in percentage between groups: Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride group - Insulin Glargine+Metformin+Glimepiride group
SecondaryGlycosylated Haemoglobin (HbA1c) Value
Time frame:
at the end of treatment (week 24)
Reported as:
Mean · percent
Glycosylated Haemoglobin (HbA1c) Value
percentInsulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+Glimepiride
Glycosylated Haemoglobin (HbA1c) Value7.5 ± 0.647.8 ± 0.85
SecondaryChange in Glycosylated Haemoglobin (HbA1c) Value
Time frame:
from baseline to the end of treatment (week 24)
Reported as:
Least squares mean · percent
Change in Glycosylated Haemoglobin (HbA1c) Value
percentInsulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+Glimepiride
Change in Glycosylated Haemoglobin (HbA1c) Value-0.37 ± 0.085-0.11 ± 0.078
Statistical analysis
  • Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride vs Insulin Glargine+Metformin+Glimepiride · ANCOVA · p = 0.029 (Threshold for statistical significance (alpha) = 0.05 ; 2 sided-test) · Mean difference (net): -0.26 · 95% CI -0.49 to -0.03Difference between groups: Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride group - Insulin Glargine+Metformin+Glimepiride group
SecondaryDaily Mean Plasma Glucose
Time frame:
at the end of treatment (week 24)
Reported as:
Mean · mg/dL
Daily Mean Plasma Glucose
mg/dLInsulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+Glimepiride
Daily Mean Plasma Glucose154.7 ± 28.62165.8 ± 37.48
SecondaryChange in Daily Mean Plasma Glucose
Time frame:
from baseline to the end of treatment (week 24)
Reported as:
Least squares mean · mg/dL
Change in Daily Mean Plasma Glucose
mg/dLInsulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+Glimepiride
Change in Daily Mean Plasma Glucose-15.01 ± 3.661-2.07 ± 3.384
Statistical analysis
  • Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride vs Insulin Glargine+Metformin+Glimepiride · ANCOVA · p = 0.0109 (Threshold for statistical significance (alpha) = 0.05 ; 2 sided-test) · Mean difference (net): -12.94 · 95% CI -22.83 to -3.04Difference between groups: Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride group - Insulin Glargine+Metformin+Glimepiride group
SecondaryChange in Weight
Time frame:
from baseline to the end of treatment (week 24)
Reported as:
Least squares mean · kg
Change in Weight
kgInsulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+Glimepiride
Change in Weight0.46 ± 0.3160.22 ± 0.293
Statistical analysis
  • Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride vs Insulin Glargine+Metformin+Glimepiride · ANCOVA · p = 0.5762 (Threshold for statistical significance (alpha) = 0.05 ; 2 sided-test) · Mean difference (net): 0.24 · 95% CI -0.61 to 1.1Difference between groups: Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride group - Insulin Glargine+Metformin+Glimepiride group
SecondaryDaily Dose of Insulin Glargine

Mean of 3 daily doses reported during the week prior to the final visit

Time frame:
at the end of treatment (week 24)
Reported as:
Mean · units of insulin glargine per day
Daily Dose of Insulin Glargine
units of insulin glargine per dayInsulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+Glimepiride
Daily Dose of Insulin Glargine54.7 ± 34.8462.2 ± 34.85
SecondaryDaily Dose of Insulin Glulisine

Mean of 3 daily doses reported during the week prior to the final visit

Time frame:
at the end of treatment (week 24)
Reported as:
Mean · units of insulin glulisine per day
Daily Dose of Insulin Glulisine
units of insulin glulisine per dayInsulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+Glimepiride
Daily Dose of Insulin Glulisine12.8 ± 6.59—
SecondaryRate of Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL
Time frame:
during treatment period (12 weeks)
Reported as:
Mean · Number of hypoglycemia per patient-year
Rate of Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL
Number of hypoglycemia per patient-yearInsulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+Glimepiride
Rate of Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL8.19 ± 14.6037.68 ± 13.996
Statistical analysis
  • Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride vs Insulin Glargine+Metformin+Glimepiride · Wilcoxon (Mann-Whitney) · p = 0.958 (Threshold for statistical significance (alpha) = 0.05 ; 2 sided-test)
SecondaryRate of Nocturnal Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL
Time frame:
during treatment period (12 weeks)
Reported as:
Mean · Number of hypoglycemia per patient-year
Rate of Nocturnal Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL
Number of hypoglycemia per patient-yearInsulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+Glimepiride
Rate of Nocturnal Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL1.62 ± 3.4183.95 ± 9.339
Statistical analysis
  • Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride vs Insulin Glargine+Metformin+Glimepiride · Wilcoxon (Mann-Whitney) · p = 0.302 (Threshold for statistical significance (alpha) = 0.05 ; 2 sided-test)
SecondaryRate of Severe Symptomatic Hypoglycemia
Time frame:
during treatment period (12 weeks)
Reported as:
Mean · Number of hypoglycemia per patient-year
Rate of Severe Symptomatic Hypoglycemia
Number of hypoglycemia per patient-yearInsulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+Glimepiride
Rate of Severe Symptomatic Hypoglycemia0.00 ± 0.0000.20 ± 1.096
Statistical analysis
  • Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride vs Insulin Glargine+Metformin+Glimepiride · Wilcoxon (Mann-Whitney) · p = 0.192 (Threshold for statistical significance (alpha) = 0.05 ; 2 sided-test)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride—1/49 (2%)0/49 (0%)
Insulin Glargine+Metformin+Glimepiride—2/57 (3.5%)0/57 (0%)
Most frequent serious events
Most frequent serious events
EventInsulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+Glimepiride
Angina PectorisCardiac disorders1/490/57
Atrial FibrillationCardiac disorders1/490/57
SclerodermaMusculoskeletal and connective tissue disorders0/491/57
Tendon DisorderMusculoskeletal and connective tissue disorders0/491/57

Baseline characteristics

Age Continuous
Age Continuous(years)Insulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+GlimepirideTotal
Mean60.6 ± 6.7359.3 ± 8.8459.9 ± 7.92
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+GlimepirideTotal
Female293564
Male202242
Region of Enrollment
Region of Enrollment(participants)Insulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+GlimepirideTotal
United States232750
United Kingdom111425
Russian Federation151631
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m²)Insulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+GlimepirideTotal
Mean33.2 ± 5.3033.3 ± 4.3933.3 ± 4.80
Daily Mean Plasma Glucose
Daily Mean Plasma Glucose(mg/dL)Insulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+GlimepirideTotal
Mean170.2 ± 27.86167.4 ± 39.41169 ± 34.33
Duration of diabetes
Duration of diabetes(years)Insulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+GlimepirideTotal
Mean12.1 ± 7.2911.0 ± 7.0211.5 ± 7.13
Glycosylated Haemoglobin (HbA1c)
Glycosylated Haemoglobin (HbA1c)(percent)Insulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+GlimepirideTotal
Mean7.8 ± 0.608.0 ± 0.677.9 ± 0.64
Weight
Weight(kg)Insulin Glulisine+Insulin Glargine+Metformin+GlimepirideInsulin Glargine+Metformin+GlimepirideTotal
Mean91.5 ± 16.6092.9 ± 17.1592.3 ± 16.83
08

Study locations

3 sites
  • Sanofi-aventis
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis
    Moscow, Russian Federation
  • Sanofi-aventis
    Guildford, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2006
First posted
Aug 7, 2006
Start
Jul 2006
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results first posted
Dec 2, 2009
Last update
Aug 8, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00360698
Lead sponsor
Sanofi
First posted
Aug 7, 2006
Start date
Jul 2006
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
Dec 2, 2009
Last update
Aug 8, 2011

Study contacts

PILORGET Valérie, MD
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin glulisine

Start the discussion